K. Izumi

M. Yasuda, T. Deguchi, K. Nakashima, 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Real-World Clinical Outcomes of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

K. Izumi, A. Mizokami, K. Shigehara, 2020 .

Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study.

H. Yaegashi, K. Izumi, A. Mizokami, 2022, Japanese journal of clinical oncology.

Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma.

K. Izumi, Y. Kitagawa, A. Mizokami, 2016, Anticancer research.

Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib

S. Yano, K. Yasumoto, K. Ohtsubo, 2010, International Journal of Clinical Oncology.

A novel risk classification score for malignant ureteral obstruction: a multicenter prospective validation study

H. Yaegashi, K. Nakashima, K. Izumi, 2021, Scientific Reports.

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice

K. Izumi, A. Mizokami, Renato Naito, 2020, Translational andrology and urology.

Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

H. Akaza, K. Izumi, Y. Kitagawa, 2014, Journal of Cancer Research and Clinical Oncology.

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan

H. Yaegashi, K. Nakashima, K. Izumi, 2014, Asian journal of andrology.

5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.

K. Izumi, A. Mizokami, Yohei Saito, 2018, European journal of medicinal chemistry.

Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer

Kyoko Takahashi, K. Izumi, A. Mizokami, 2021, ACS omega.

CCL5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment

Wen-Jye Lin, K. Izumi, A. Mizokami, 2018 .

Diagnostic accuracy of pre-operative imaging findings in presumed clinical T1a renal cell carcinomas.

K. Nakashima, K. Izumi, Y. Kitagawa, 2016, Oncology letters.

Factors Associated With Treatment Satisfaction After Robot-assisted Radical Prostatectomy

H. Yaegashi, K. Izumi, A. Mizokami, 2019, AntiCancer Research.

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

N. Kawai, H. Enokida, T. Okamura, 2022, European urology open science.

Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy

H. Yaegashi, K. Nakajima, K. Nakashima, 2019, AntiCancer Research.

Impact of Pelvic Anatomical Changes Caused by Radical Prostatectomy

H. Yaegashi, K. Izumi, A. Mizokami, 2022, Cancers.

Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2020, AntiCancer Research.

Comparison of testosterone fractions in Framingham Heart Study subjects and Japanese subjects Comparison of testosterone fractions

T. Iwamoto, K. Izumi, M. Namiki, 2014 .

Comparison of testosterone fractions between Framingham Heart Study participants and Japanese participants

T. Iwamoto, K. Izumi, M. Namiki, 2014, International journal of urology : official journal of the Japanese Urological Association.

Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus

K. Nakashima, K. Izumi, A. Mizokami, 2018, International Journal of Impotence Research.

Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

S. Yeh, Chawnshang Chang, Chiung-Kuei Huang, 2013, Molecular endocrinology.

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

S. Yeh, C. Chang, K. Izumi, 2013, Cell Death and Disease.

synthesis of T and DHT from DHEA.

K. Izumi, A. Mizokami, K. Narimoto, 2009 .

Influence of the Coronavirus Disease 2019 Vaccine on Drug Therapy for Urological Cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2022, AntiCancer Research.

Epidemiology and Prevention of Renal Cell Carcinoma

K. Izumi, A. Mizokami, Suguru Kadomoto, 2022, Cancers.

Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure?

H. Yaegashi, K. Izumi, A. Mizokami, 2021, Journal of Robotic Surgery.

K. Nakashima, K. Izumi, A. Mizokami, 2019, AntiCancer Research.

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice

K. Izumi, Y. Kitagawa, A. Mizokami, 2016, Asian journal of andrology.

Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as second-line hormonal therapy

K. Izumi, A. Mizokami, M. Namiki, 2009 .

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients

K. Izumi, M. Namiki, A. Maolake, 2014, Oncology letters.

Running Head: Pembrolizumab for UC with small lesions-Kadono et al. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST

K. Izumi, A. Mizokami, K. Shigehara, 2021 .

Treatment at an Inexperienced Center Suggests Worse Prognosis of Metastatic Germ Cell Tumors.

H. Yaegashi, K. Izumi, A. Mizokami, 2021, Cancer diagnosis & prognosis.

Clinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma.

H. Yaegashi, K. Izumi, A. Mizokami, 2021, Cancer diagnosis & prognosis.

The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2020, AntiCancer Research.

Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma.

K. Izumi, A. Mizokami, Hiroaki Iwamoto, 2016, Anticancer research.

Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.

K. Izumi, A. Mizokami, Hiroaki Iwamoto, 2018, Anticancer research.

Second‐line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second‐line Studies

J. Carles, S. Srinivas, D. Vis, 2017, Clinical genitourinary cancer.

Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor

K. Izumi, A. Mizokami, Hiroaki Iwamoto, 2018, In Vivo.

Cumulative probability of prostate cancer detection using the international prostate symptom score in a prostate-specific antigen-based population screening program in Japan.

K. Izumi, Y. Kitagawa, A. Mizokami, 2014, Asian Pacific journal of cancer prevention : APJCP.

Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer

H. Yaegashi, K. Izumi, Y. Kitagawa, 2014, Journal of Cancer Research and Clinical Oncology.

Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study

T. Shimada, Y. Sai, K. Izumi, 2017, Journal of Pharmaceutical Health Care and Sciences.

Inflammatory Myofibroblastic Tumor of the Urinary Bladder with Benign Pelvic Lymph Node Enlargement: A Case Report

H. Ikeda, K. Izumi, Y. Kitagawa, 2014, Case Reports in Oncology.

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

H. Yaegashi, K. Izumi, A. Mizokami, 2022, Frontiers in Oncology.

Effectiveness of Synthetic Polymer-coated Peripherally Inserted Central Catheter in Patients With Advanced Cancer

K. Izumi, A. Mizokami, Hiroaki Iwamoto, 2019, In Vivo.

Relationship between Testosterone and Sarcopenia in Older-Adult Men: A Narrative Review

K. Izumi, A. Mizokami, K. Shigehara, 2022, Journal of clinical medicine.

The correlation between erectile function and adiponectin levels in men with late-onset hypogonadism

K. Izumi, A. Mizokami, M. Namiki, 2022, The aging male : the official journal of the International Society for the Study of the Aging Male.

A Novel Scoring System to Predict the Risk for Disseminated Intravascular Coagulation in Obstructive Pyelonephritis Complicated with Upper Urinary Tract Calculi

K. Izumi, A. Mizokami, Hiroaki Iwamoto, 2019 .

New molecular diagnostic kit to assess Y‐chromosome deletions in the Japanese population

K. Izumi, M. Namiki, E. Koh, 2014, International journal of urology : official journal of the Japanese Urological Association.

Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2022, IJU case reports.

A new flavonoid derivative exerts antitumor effects against androgen‐sensitive to cabazitaxel‐resistant prostate cancer cells

H. Yaegashi, K. Izumi, A. Mizokami, 2021, The Prostate.

Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone.

Jian Zhang, E. Keller, K. Izumi, 2013, Anticancer research.

Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2022, Anticancer Research.

Optimal treatment for castration-resistant prostate cancer

K. Izumi, M. Namiki, 2014, Asian journal of andrology.

Efficacy of combined prophylactic use of levofloxacin and isepamicin for transrectal prostate needle biopsy: A retrospective single-center study.

K. Izumi, A. Mizokami, K. Shigehara, 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

SHORT-TERM EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY ON RISK PREDICTORS FOR ARTERIOSCLEROSIS AMONG MEN WITH LATE-ONSET HYPOGONADISM: A CASE–CONTROL STUDY

K. Izumi, A. Mizokami, M. Namiki, 2020 .

Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2022, Biomedicines.

Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis

H. Yaegashi, K. Izumi, A. Mizokami, 2019, Cancers.

The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study

H. Yaegashi, K. Izumi, A. Mizokami, 2021, International Journal of Clinical Oncology.

Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.

Jian Zhang, E. Keller, K. Izumi, 2018, Anticancer research.

SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation.

Jian Zhang, E. Keller, K. Izumi, 2014, Anticancer research.

Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men

H. Yaegashi, Kotaro Yoshida, K. Izumi, 2022, Cancers.

Risk factors for human papillomavirus detection in urine samples of heterosexual men visiting urological clinics in Japan.

H. Yaegashi, K. Nakashima, T. Kitamura, 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study).

S. Yano, K. Ohtsubo, Tadaaki Yamada, 2017, The journal of medical investigation : JMI.

A Case Report of Chyloretroperitoneum Post Living-Donor Transplantation

H. Yaegashi, K. Nakashima, K. Izumi, 2019, Urologia internationalis.

Active estrogen synthesis and its function in prostate cancer-derived stromal cells.

K. Izumi, A. Mizokami, M. Namiki, 2015, Anticancer research.

Use of preoperative factors including urodynamic evaluations and nerve‐sparing status for predicting urinary continence recovery after robot‐assisted radical prostatectomy: Nerve‐sparing technique contributes to the reduction of postprostatectomy incontinence

K. Nakashima, K. Izumi, A. Mizokami, 2016, Neurourology and urodynamics.

Reiter’s syndrome following intravesical Bacillus Calmette-Guerin therapy for bladder carcinoma: a report of five cases

H. Yaegashi, K. Nakashima, K. Izumi, 2018, International Cancer Conference Journal.

Androgen receptor roles in the development of benign prostate hyperplasia.

Chawnshang Chang, Wen-Jye Lin, K. Izumi, 2013, The American journal of pathology.

Roles of CCL2-CCR2 Axis in the Tumor Microenvironment

K. Izumi, A. Mizokami, S. Kadomoto, 2021, International journal of molecular sciences.

Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.

Chawnshang Chang, H. Miyamoto, Lei Li, 2013, Cancer research.

Abstract. Germ cell tumors with somatic‐type malignancy (GCTSTM) are rare, and patients with GCTSTM have extremely poor prognoses with a median survival of nine

H. Yaegashi, K. Izumi, A. Mizokami, 2021 .

Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.

E. Keller, K. Izumi, A. Mizokami, 2009, Endocrine-related cancer.

Macrophage Polarity and Disease Control

K. Izumi, A. Mizokami, S. Kadomoto, 2021, International journal of molecular sciences.

The CCL20-CCR6 Axis in Cancer Progression

K. Izumi, A. Mizokami, S. Kadomoto, 2020, International journal of molecular sciences.

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment

K. Izumi, A. Mizokami, T. Makino, 2021, Biomedicines.

Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma

K. Izumi, A. Mizokami, K. Shigehara, 2021, AntiCancer Research.

The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status12

Hong-Chiang Chang, Chawnshang Chang, H. Miyamoto, 2015, Neoplasia.

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report

H. Yaegashi, K. Izumi, A. Mizokami, 2022, Frontiers in Oncology.

Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Chawnshang Chang, Lei Li, K. Izumi, 2014, Clinical investigation.

Are bladder washing samples suitable for investigation of HPV infection in urinary bladder? Comparison in HPV prevalence between urine and washing samples

K. Izumi, A. Mizokami, K. Shigehara, 2022, Journal of medical virology.

Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.

K. Izumi, A. Mizokami, M. Namiki, 2010, Anticancer research.

Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction.

K. Izumi, A. Mizokami, M. Namiki, 2011, The Journal of urology.

Down‐regulation of calcium/calmodulin‐dependent protein kinase kinase 2 by androgen deprivation induces castration‐resistant prostate cancer

Toru Miyagi, Jian Zhang, E. Keller, 2012, The Prostate.

Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells

K. Izumi, A. Mizokami, Yohei Saito, 2018, The Prostate.

Tumor necrosis factor‐α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation

K. Nastiuk, K. Izumi, A. Mizokami, 2018, Cancer science.

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation

Chawnshang Chang, Lei Li, Wen-Jye Lin, 2013, EMBO molecular medicine.

Comparison of the Prognostic Value of Inflammatory and Nutritional Indices in Nonmetastatic Renal Cell Carcinoma

K. Izumi, A. Mizokami, Y. Kadono, 2023, Biomedicines.

International Journal of Clinical Oncology

Y. Zen, S. Yano, K. Yasumoto, 2009 .

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer

Chiung-Kuei Huang, H. Miyamoto, Wen-Jye Lin, 2015, Oncotarget.

Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer

K. Izumi, A. Mizokami, T. Makino, 2021, Cancers.

Incidences of visceral metastases from prostate cancer increase after progression of castration-resistant status.

K. Izumi, A. Mizokami, Y. Kadono, 2018 .

Treatment Outcomes in Neuroendocrine Prostate Cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2022, AntiCancer Research.

Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer

T. Shimada, H. Yaegashi, Y. Sai, 2020, AntiCancer Research.

Cranial nerve deficit caused by skull metastasis of prostate cancer: three Japanese castration-resistant prostate cancer cases

K. Izumi, A. Mizokami, M. Namiki, 2010, International Journal of Clinical Oncology.

Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy

K. Nakashima, K. Izumi, A. Mizokami, 2020, Translational andrology and urology.

Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.

K. Izumi, A. Mizokami, M. Namiki, 2010, Anticancer research.

Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1‐associated osteoblastic changes

E. Keller, K. Izumi, Y. Kitagawa, 2009, The Prostate.

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines

Jian Zhang, E. Keller, K. Izumi, 2018, Oncotarget.

Reply to Comment on “Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis” Cancers 2020, 12, 89

H. Yaegashi, K. Izumi, A. Mizokami, 2020, Cancers.

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

N. Kawai, K. Ishibashi, H. Enokida, 2017, BMC Cancer.

The relationship between prostate‐specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate‐specific antigen levels

H. Ikeda, K. Izumi, Y. Kitagawa, 2015, The Prostate.

Androgen and Androgen Receptor in Kidney Cancer

Chiung-Kuei Huang, K. Izumi, Joshua Cho, 2015 .

Overexpression of p54nrb/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth

H. Aburatani, T. Kodama, M. Anai, 2018, Oncotarget.

Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism

K. Nakashima, K. Izumi, Y. Kitagawa, 2017, BJU international.

Decreased febrile neutropenia during inpatient chemotherapy for urologic cancer during coronavirus disease 2019 pandemic

H. Yaegashi, K. Izumi, A. Mizokami, 2023 .

Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells

T. Shimada, H. Yaegashi, T. Wada, 2021, Scientific reports.

A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.

K. Izumi, A. Mizokami, M. Namiki, 2009, Japanese journal of clinical oncology.

Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells

K. Izumi, A. Mizokami, 2019, Journal of clinical medicine.

An important step in establishing a treatment strategy for small renal masses of clear cell renal cell carcinoma based on the significance of adverse histopathologic features on tumor needle biopsy.

K. Izumi, A. Mizokami, T. Makino, 2019, Annals of translational medicine.

The role of percutaneous needle biopsy in differentiation of renal tumors.

S. Yano, Tadaaki Yamada, K. Izumi, 2010, Japanese journal of clinical oncology.

Parenchymal Suture-Assisted Inner Suture Method: Tips to Achieve a Reliable Inner Suture in Partial Nephrectomy

K. Izumi, A. Mizokami, K. Shigehara, 2021, Videourology.

Severe Renal Hemorrhage in a Pregnant Woman Complicated with Antiphospholipid Syndrome: A Case Report

K. Izumi, A. Mizokami, M. Namiki, 2011, Advances in urology.

Ectopic ureter accompanied by giant ureteral stone and pyonephrosis

K. Izumi, M. Namiki, H. Kato, 2007, International journal of urology : official journal of the Japanese Urological Association.

Prevalence of N. gonorrhoeae, C. trachomatis, M. genitalium, M. hominis and Ureaplasma spp. in the anus and urine among Japanese HIV-infected men who have sex with men.

H. Yaegashi, K. Nakashima, K. Izumi, 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: The role of procalcitonin

H. Yaegashi, K. Izumi, Y. Kitagawa, 2014, International journal of urology : official journal of the Japanese Urological Association.

The role of procalcitonin in differentiation between bacterial infection and neoplastic fever in patients with advanced urological cancer

H. Yaegashi, K. Izumi, Y. Kitagawa, 2014 .

C‐C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment

Wen-Jye Lin, K. Izumi, A. Mizokami, 2018, Cancer science.

Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal‐related events in patients with prostate cancer with bone metastasis

K. Izumi, A. Mizokami, M. Namiki, 2012, BJU international.

Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2021, In Vivo.

Age‐specific reference range of prostate‐specific antigen and prostate cancer detection in population‐based screening cohort in Japan: Verification of Japanese Urological Association Guideline for prostate cancer

K. Izumi, Y. Kitagawa, A. Mizokami, 2014, International journal of urology : official journal of the Japanese Urological Association.

Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1–10.0 ng/ml at population screening

K. Izumi, Y. Kitagawa, A. Mizokami, 2013, Journal of Cancer Research and Clinical Oncology.

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer

K. Izumi, A. Mizokami, T. Makino, 2022, Cancers.

Role of Surgical Resection in Adult Urological Soft Tissue Sarcoma: 25-Year Experience

K. Izumi, Y. Kitagawa, A. Mizokami, 2010, Urologia Internationalis.

α-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer

K. Izumi, A. Mizokami, Yohei Saito, 2021, Molecules.

Low free testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors

K. Izumi, A. Mizokami, M. Namiki, 2021, The aging male : the official journal of the International Society for the Study of the Aging Male.

Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study)

H. Yaegashi, S. Yano, Tadaaki Yamada, 2021, Journal of cachexia, sarcopenia and muscle.

Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy

H. Yaegashi, K. Izumi, A. Mizokami, 2021, In Vivo.

Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial

Y. Fujii, G. Kimura, K. Izumi, 2019, International Journal of Clinical Oncology.

Novel Prevention Procedure for Inguinal Hernia after Robot-Assisted Radical Prostatectomy: Results from a Prospective Randomized Trial.

H. Yaegashi, K. Nakashima, K. Izumi, 2019, Journal of endourology.

Clinical results of iridium-192 high dose rate brachytherapy with external beam radiotherapy.

K. Izumi, A. Mizokami, M. Namiki, 2010, Japanese journal of clinical oncology.

Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: A subanalysis of a prospective randomised controlled study in Japan (EARTH study)

K. Izumi, A. Mizokami, K. Shigehara, 2020, Andrologia.

Changes in penile length after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy

K. Nakashima, K. Izumi, A. Mizokami, 2018, Andrology.

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist

K. Izumi, A. Mizokami, M. Namiki, 2013, Case Reports in Nephrology and Dialysis.

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells

Wen-Jye Lin, K. Izumi, A. Mizokami, 2018, Cancer science.

Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9® to better battle prostate cancer progression

Chawnshang Chang, K. Izumi, 2013, Oncoimmunology.

Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9® to better battle prostate cancer progression

Chawnshang Chang, K. Izumi, 2013, Oncoimmunology.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level

Chiung-Kuei Huang, H. Miyamoto, Wen-Jye Lin, 2014, Journal of Cancer Research and Clinical Oncology.

Androgen receptor signaling‐targeted therapy and taxane chemotherapy induce visceral metastasis in castration‐resistant prostate cancer

H. Yaegashi, K. Izumi, A. Mizokami, 2020, The Prostate.

Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival.

H. Yaegashi, K. Izumi, A. Mizokami, 2023, Photodiagnosis and photodynamic therapy.

Adrenal androgen levels as predictors of outcome in castration‐resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second‐line anti‐androgen

K. Izumi, A. Mizokami, M. Namiki, 2010, International journal of urology : official journal of the Japanese Urological Association.

Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital

H. Yaegashi, K. Nakashima, S. Matsuo, 2019, AntiCancer Research.

Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?

H. Yaegashi, K. Izumi, A. Mizokami, 2023, AntiCancer Research.

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL

K. Izumi, A. Mizokami, Y. Kadono, 2019, International braz j urol : official journal of the Brazilian Society of Urology.

Detection of serum hepatitis B Virus antigen and hepatitis C virus antibody from prostate cancer patients in Japan

M. Yao, Y. Kubota, K. Izumi, 2017 .

Factors predictive of oncological outcome after nephroureterectomy: comparison between laparoscopic and open procedures.

K. Izumi, Y. Kitagawa, A. Mizokami, 2013, Anticancer research.

Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.

H. Yaegashi, K. Izumi, Y. Kitagawa, 2013, Anticancer research.

Urodynamic evaluation before and immediately after robot-assisted radical prostatectomy.

H. Yaegashi, K. Izumi, A. Mizokami, 2014, Urology.

Laparoscopy and Robotics Urodynamic Evaluation Before and Immediately After Robot-assisted Radical Prostatectomy

H. Yaegashi, K. Izumi, A. Mizokami, 2014 .

Intrapelvic fat makes robot-assisted radical prostatectomy difficult.

K. Izumi, M. Namiki, Y. Kadono, 2014, Anticancer research.

Title Metastatic renal cell carcinoma complicated with diffuse alveolarhemorrhage : a rare adverse effect of sunitinib

S. Yano, K. Yasumoto, K. Ohtsubo, 2017 .

Aplastic anemia associated with severe hemorrhagic cystitis following radiotherapy for prostate cancer.

K. Izumi, Y. Kitagawa, A. Mizokami, 2016, Molecular and clinical oncology.

Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma.

H. Miyamoto, K. Izumi, Y. Zheng, 2012, Current cancer drug targets.

Metanephric adenoma treated with laparoscopic nephrectomy: A case report.

H. Ikeda, K. Izumi, A. Mizokami, 2017, Molecular and clinical oncology.

Postoperative functional and cancer control evaluation of conventional and Retzius‐sparing robot‐assisted radical prostatectomy: Comparison of selected cases by propensity score matching

H. Yaegashi, K. Izumi, A. Mizokami, 2023, The Prostate.

Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.

K. Izumi, Y. Kitagawa, A. Mizokami, 2013, Anticancer research.

Does Bladder Cancer with Inchworm Sign Indicate Better Prognosis after TURBT?

H. Yaegashi, Kotaro Yoshida, K. Izumi, 2022, Cancers.

Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function

H. Yaegashi, K. Izumi, A. Mizokami, 2018, In Vivo.

Comparison of Clinical Outcomes between Robot-Assisted Partial Nephrectomy and Cryoablation in Elderly Patients with Renal Cancer

H. Yaegashi, Kotaro Yoshida, K. Izumi, 2022, Cancers.

A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age

H. Yaegashi, K. Izumi, A. Mizokami, 2020, Asian journal of andrology.

Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.

K. Izumi, A. Mizokami, M. Namiki, 2009, Urology.

Carbon dioxide gas embolism during robot‐assisted laparoscopic partial nephrectomy

H. Yaegashi, K. Izumi, A. Mizokami, 2022, IJU Case Reports.

Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study

S. Anai, N. Kawai, K. Ishibashi, 2023, Cancers.

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

T. Takahara, H. Yaegashi, Y. Yoshioka, 2023, BMC Urology.

T. Shimada, Y. Sai, K. Izumi, 2017, Journal of pharmaceutical health care and sciences.

Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20–CCR6 axis

H. Yaegashi, Wen-Jye Lin, K. Izumi, 2022, Cancer Science.

Editorial Comment to Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan

K. Izumi, 2018, International journal of urology : official journal of the Japanese Urological Association.

Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy

K. Izumi, A. Mizokami, K. Shigehara, 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.

The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma

H. Yaegashi, K. Izumi, A. Mizokami, 2020, AntiCancer Research.

Abstract 85: Establishment of cabazitaxel-resistant prostate cancer cell lines

E. Keller, K. Izumi, A. Mizokami, 2017 .

Clinicopathological outcomes of clinical T1a renal cell carcinoma by tumor size.

K. Nakashima, K. Izumi, Y. Kitagawa, 2011, Japanese journal of clinical oncology.

Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report

H. Yaegashi, K. Izumi, A. Mizokami, 2015, Journal of Medical Case Reports.

H. Yaegashi, H. Ikeda, K. Izumi, 2021, Anticancer Research.

Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells

H. Yaegashi, K. Izumi, A. Mizokami, 2023, AntiCancer Research.

Tranilast InhibitsHormoneRefractory Prostate CancerCell ProliferationandSuppressesTransforming Growth Factor b 1-AssociatedOsteoblastic Changes

E. Keller, K. Izumi, Y. Kitagawa, 2009 .

Transvaginal polytetrafluoroethylene mesh surgery for pelvic organ prolapse: 1‐year clinical outcomes

H. Yaegashi, M. Koyama, K. Izumi, 2020, International journal of urology : official journal of the Japanese Urological Association.

CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer

Jian Zhang, E. Keller, K. Izumi, 2010, The Prostate.

Histiocytic sarcoma following combination chemotherapy for primary mediastinal germ cell tumor: a diagnostic dilemma

K. Harada, H. Yaegashi, Yasunori Sato, 2021, International Cancer Conference Journal.

Editorial for the Special Issue on High-Risk Localized and Locally Advanced Prostate Cancer

K. Izumi, 2023, Cancers.

The five-year effects of testosterone replacement therapy on lipid profile and glucose tolerance among hypogonadal men in Japan: a case control study

K. Nakashima, K. Izumi, A. Mizokami, 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

N. Kawai, K. Ishibashi, H. Enokida, 2017, BMC Cancer.

Editorial Comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration‐resistant prostate cancer in men

K. Izumi, 2018, International journal of urology : official journal of the Japanese Urological Association.

Comparison of postoperative urinary continence and incontinence types between conventional and Retzius‐sparing robot‐assisted radical prostatectomy

H. Yaegashi, K. Izumi, A. Mizokami, 2023, Neurourology and urodynamics.

Investigating the mechanism underlying urinary continence using dynamic MRI after Retzius-sparing robot-assisted radical prostatectomy

Kotaro Yoshida, K. Izumi, A. Mizokami, 2021, Scientific Reports.

Investigating Urinary Conditions Prior to Robot-assisted Radical Prostatectomy in Search of a Desirable Method for Evaluating Post-prostatectomy Incontinence.

K. Nakashima, K. Izumi, A. Mizokami, 2016, Anticancer Research.

Title Outcomes and predictive factors of prostate cancer patients with extremelyhigh prostate-specific antigen level

Chiung-Kuei Huang, H. Miyamoto, K. Izumi, 2017 .

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study

S. Anai, N. Kawai, K. Ishibashi, 2019, Contemporary clinical trials communications.

Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review

H. Yaegashi, K. Izumi, A. Mizokami, 2019, The world journal of men's health.

Contribution of Retzius-sparing robot-assisted radical prostatectomy to the mechanism of urinary continence as demonstrated by dynamic MRI

H. Yaegashi, Kotaro Yoshida, K. Izumi, 2023, Scientific Reports.

Decreased febrile neutropenia during inpatient chemotherapy for urologic cancer during coronavirus disease 2019 pandemic

H. Yaegashi, K. Izumi, A. Mizokami, 2022, Cancer science.

Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy

Kouji Izumi, Hiroaki Iwamoto, Hiroshi Yaegashi, 2021, In Vivo.

Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.

M. Galsky, S. Park, E. Kikuchi, 2021 .

Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130

M. Galsky, S. Park, P. O’Donnell, 2021, Clinical Trials.

Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.

S. Park, E. Kikuchi, I. Davis, 2023, Journal of Clinical Oncology.

Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.

S. Park, P. O’Donnell, E. Kikuchi, 2023, Journal of Clinical Oncology.

Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience.

H. Yaegashi, H. Ikeda, K. Ohtsubo, 2022, Cancer diagnosis & prognosis.

Editorial Comment from Dr Izumi to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate‐specific antigen‐based screening in Yokosuka and those detected by other means

K. Izumi, 2015, International journal of urology : official journal of the Japanese Urological Association.

[Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma].

S. Yano, K. Yasumoto, K. Ohtsubo, 2010, Gan to kagaku ryoho. Cancer & chemotherapy.

High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma

H. Yaegashi, K. Izumi, A. Mizokami, 2019, AntiCancer Research.

Combination of Sarcopenia and Hypoalbuminemia Is a Poor Prognostic Factor in Surgically Treated Nonmetastatic Renal Cell Carcinoma

K. Izumi, A. Mizokami, T. Makino, 2023, Biomedicines.

Sarcopenia Is Associated With Aggressive Clinicopathological Outcomes and Is a Poor Prognostic Indicator for Non-metastatic Renal Cell Carcinoma

K. Izumi, A. Mizokami, Y. Kadono, 2023, In Vivo.

Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130

M. Galsky, S. Park, M. Santis, 2021, Clinical Trials.

Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal‐related events in patients with prostate cancer with bone metastasis

K. Izumi, A. Mizokami, M. Namiki, 2012, BJU international.

Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma

H. Yaegashi, K. Izumi, A. Mizokami, 2022, In Vivo.

Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.

K. Izumi, Y. Kitagawa, A. Mizokami, 2013, Anticancer research.

698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

M. Galsky, E. Kikuchi, I. Davis, 2020 .